Nanordica's Premotiv® dressing has demonstrated a 43% reduction in wound area size after just one week of treatment compared to 13% with standard silver dressings in a randomized controlled trial on 30 patients with diabetic foot ulcers.

In addition to this already published study, we are currently conducting a multicentered, double-blind, randomized clinical trial in patients with diabetic foot ulcers. With more than 120 patients already enrolled, it is one of the largest studies of its kind. It is expected to generate strong clinical evidence supporting reimbursement, future treatment guideline recommendations and broader clinical adoption of Nanordica Medical's technology.

"Current diabetic foot treatment guidelines are not fully aligned with everyday clinical practice, where there is a clear need for effective antibacterial dressings", said Prof. Dr. José Luis Lázaro-Martínez, the Chair of the Diabetic Foot Committee of the EWMA • European Wound Management Association and the Principal Investigator of Nanordica Medical's multicentered trial. "Antibacterial dressings supported by robust clinical evidence may influence future guideline recommendations and become category-defining solutions."

The funding will enable us to complete a multicenter randomized clinical study, strengthen the economic case for Premotiv® wound dressing and finalize CE marking for commercial launch in Europe.

The round was led by Estonian fund 2C Ventures with participation from existing investors, Specialist VC, Superangel, Amalfi, Health Founders syndicate led by Erki Mölder and Estonian Business Angels Network (EstBAN) syndicate led by Heidi Kakko and Martin Gorosko.

Full press release ↗